- Home
- NVO vs AZN Comparison
NVO vs AZN Comparison
Compare NVO & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVO
- AZN
- Stock Information
- Founded
- NVO 1923
- AZN 1992
- Country
- NVO Denmark
- AZN United Kingdom
- Employees
- NVO N/A
- AZN N/A
- Industry
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- NVO Health Care
- AZN Health Care
- Exchange
- NVO Nasdaq
- AZN Nasdaq
- Market Cap
- NVO 278.0B
- AZN 228.9B
- IPO Year
- NVO N/A
- AZN 1993
- Fundamental
- Price
- NVO $73.79
- AZN $69.95
- Analyst Decision
- NVO Buy
- AZN Strong Buy
- Analyst Count
- NVO 3
- AZN 3
- Target Price
- NVO $112.00
- AZN $95.00
- AVG Volume (30 Days)
- NVO 8.9M
- AZN 4.0M
- Earning Date
- NVO 08-06-2025
- AZN 07-24-2025
- Dividend Yield
- NVO 2.18%
- AZN 2.21%
- EPS Growth
- NVO 17.93
- AZN 22.71
- EPS
- NVO 3.40
- AZN 4.97
- Revenue
- NVO $43,922,211,349.00
- AZN $54,982,000,000.00
- Revenue This Year
- NVO $18.59
- AZN $9.56
- Revenue Next Year
- NVO $15.61
- AZN $6.09
- P/E Ratio
- NVO $21.75
- AZN $14.05
- Revenue Growth
- NVO 24.11
- AZN 15.48
- 52 Week Low
- NVO $57.00
- AZN $61.24
- 52 Week High
- NVO $148.15
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- NVO 52.32
- AZN 42.41
- Support Level
- NVO $70.58
- AZN $72.18
- Resistance Level
- NVO $81.44
- AZN $75.38
- Average True Range (ATR)
- NVO 1.66
- AZN 1.03
- MACD
- NVO -0.27
- AZN -0.36
- Stochastic Oscillator
- NVO 29.51
- AZN 5.07
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.